Searching for Solutions

2025 Recertification Editorial Board Jade Abudia, PharmD, BCPP Augusta, GA No Relevant Financial Relationships to Disclose

No summary available

New Learning Collaborative from SMI TTAC on July 15: Neurobiology and Recovery: Addressing Nicotine Use Among Individuals with Serious Mental Illness

We are cross promoting this event being held by the Smoking Cessation Leadership Center. They will dive into the neurobiology of nicotine addiction in individuals with serious mental illness (SMI), review promising evidence-based interventions and discuss how tobacco treatment can be effectively integrated into psychiatric and behavioral health systems. The session will support clinicians, public health professionals and behavioral health leaders in advancing tobacco-free recovery. CEUs are available for this event.
Learn More

New Learning Collaborative from SMI TTAC on July 14: Co-Occurring SMI and SUD Learning Series | Session 3: Intersections of Methamphetamine-Induced Psychosis and Schizophrenia Spectrum Disorders

Methamphetamine-induced psychosis and schizophrenia spectrum disorders intersect in a complex clinical landscape. This webinar will deepen your understanding and improve treatment and care for people experiencing co-occurring serious mental illness (SMI) and stimulant use disorders. This session will be clinically focused. CEUs are not available for this event, but a certificate of attendance will be provided to attendees.
Learn More

Trends in Past-month Cannabis Use Among Older Adults

In this cross-sectional study published in JAMA Internal Medicine, researchers analyzed data from the 2021-2023 National Survey on Drug Use and Health and found that past-month cannabis use among U.S. adults ages 65 and older rose from 4.8% to 7.0%. The greatest increases were among people with higher incomes, more education and chronic diseases and those living in states with legalized medical cannabis.
Learn More

Trends in Suspected Fentanyl-involved Nonfatal Overdose Emergency Department Visits

In this Morbidity and Mortality Weekly Report (MMWR), emergency department (ED) data from October 2020 to March 2024 show that rates of suspected fentanyl-involved nonfatal overdose visits rose steadily across most demographic groups through mid-2023 before declining slightly. The increase highlights both the ongoing public health burden and the critical role of ED-based interventions.
Learn More

Prescription Stimulant Use Disorder Among U.S. Adults Aged 18 to 64 Years

Using cross-sectional data from national surveys and prescription records between 2019 and 2022, this study found that among U.S. adults ages 18-64 who used prescription stimulants, 25.3% reported nonmedical use and 9.0% met criteria for prescription stimulant use disorder (PSUD), with highest prevalence linked to amphetamine use, highlighting the need for PSUD screening and treatment regardless of reported use patterns.
Learn More

Cardiovascular Risk Associated With the Use of Cannabis and Cannabinoids

This systematic review and meta-analysis of real-world data connects cannabis use with an increased risk of major adverse cardiovascular events, including stroke (RR 1.20), acute coronary syndrome (RR 1.29) and cardiovascular death (RR 2.10), highlighting the need for routine screening of cannabis use in patients with serious cardiovascular conditions.
Learn More

Pharmacy residency training is considered the gold standard for pharmacists interested in practicing in direct patient care roles across community and inpatient settings. For those wishing to specialize in psychiatric pharmacy, completing a PGY2 psychiatric pharmacy residency is the most efficient process to train qualified psychiatric pharmacist specialists who are eligible to become board-certified in psychiatric pharmacy (BCPP).

Thank you to our 2025 abstract and award reviewers for their volunteer service! Jade Abudia, PharmD, BCPP Makenzie Harrison, PharmD Mackenzie Pierce, PharmD, BCPS, BCPP